VivoSeq
Respiratory

Idiopathic Pulmonary Fibrosis

155

Pipeline Programs↗

48

Active Trials↗

69

Companies Involved↗

Idiopathic Pulmonary Fibrosis is a highly competitive landscape with 155 programs across 69 companies. The most active players are Theravance Biopharma, Wuhan Optics Valley Vcanbiopharma Co., Ltd., Rein Therapeutics. 12 therapies are approved with 27 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

78/100

Pipeline Velocity

47/100

Mech. Concentration

13/100

Completion Rate

76/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

Theravance Biopharma

1 program

Phase 1W

Wuhan Optics Valley Vcanbiopharma Co., Ltd.

1 program

Phase 1R

Rein Therapeutics

1 program

Phase 1Sun Pharma logo

Sun Pharma

1 program

Phase 1S

Sclnow Biotechnology Co., Ltd.

1 program

Phase 1C

Contineum Therapeutics

3 programs

Phase 2

Pipeline

Programs by Phase

Preclinical9

Interferon Gamma-1b

Horizon Therapeutics Ireland DAC

Nintedanib

Boehringer Ingelheim

Losartan

Organon and Co

Dabigatran

Boehringer Ingelheim

Blood Withdrawn

Emergent BioSolutions

Phase 126

Valganciclovir

Engelhard Arzneimittel GmbH & Co.KG

Nitric Oxide

Mallinckrodt

Quercetin

Mayo Clinic

Octreotide

Sun Pharma

Atezolizumab

Roche

Phase 281

Macitentan

Johnson & Johnson

Lebrikizumab

Eli Lilly

Omeprazole

Dexcel Pharma Technologies Ltd.

Gefapixant

Merck & Co.

Belumosudil

Kadmon, a Sanofi Company

Phase 327

Morphine Sulfate

Merck & Co.

Cyclophosphamide

Baxter Healthcare Corporation

Thalidomide

Bristol-Myers Squibb

Methylprednisolone Sodium Succinate

Massachusetts Eye and Ear Infirmary

Warfarin

Abbott

Approved12

Acetylcysteine

Arbor Pharmaceuticals, Inc.

Treprostinil

United Therapeutics

Doxycycline

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Beclomethasone Dipropionate

Schering-Plough

Albuterol

Glaxo Dba Glaxosmithkline

Analysis

Modality Breakdown

88%

Small molecule

143 of 163 classified programs — the dominant modality here.

12%ALL OTHERSMonoclonal antibody106%Cell therapy64%Protein / enzyme32%Peptide1<1%

Small molecule leads; the ring shows all 163 classified programs, each share of the total. Modality classified for 96% of 180 pipeline programs.

Analysis

Trial Status

216

clinical trials

Completed118 · 55%
Recruiting30 · 14%
Terminated29 · 13%
Unknown status10 · 5%
Not yet recruiting9 · 4%
Active, not recruiting8 · 4%
Other12 · 6%

Clinical Trials

Trial Activity

216 trials

Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Recruiting·FFondation Hôpital Saint-Joseph·Phase 3·NCT05674994·110 enrolled
Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
Recruiting·UUniversity of Alabama at Birmingham·Phase 1·NCT04362644·10 enrolled
Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
Recruiting·UUniversity of Virginia·Phase 1·NCT06853145·6 enrolled
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
Recruiting·AbbVie logoAbbVie·Phase 2·NCT07230288·165 enrolled
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
Recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2·NCT06241560·20 enrolled
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
Recruiting·CCalluna Pharma AS·Phase 2·NCT06736990·150 enrolled
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Recruiting·SSyndax Pharmaceuticals·Phase 2·NCT06132256·135 enrolled
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
Recruiting·IInSilico Medicine Hong Kong Limited·Phase 2·NCT05975983·40 enrolled
Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Recruiting·—·N/A·NCT05842681·30 enrolled
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis
Recruiting·MMannkind Corporation·Phase 1·NCT07344558·24 enrolled
A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Recruiting·BBeijing Tide Pharmaceutical Co., Ltd·Phase 3·NCT07464912·508 enrolled
Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Recruiting·—·Phase 3·NCT07299695·196 enrolled
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
Recruiting·SShanghai Synvida Biotechnology Co.,Ltd.·Phase 2·NCT07121413·48 enrolled
Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Recruiting·WWuhan Optics Valley Vcanbiopharma Co., Ltd.·Phase 1·NCT06230822·9 enrolled
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Recruiting·CCumberland Pharmaceuticals·Phase 2·NCT05571059·128 enrolled
Page 1 of 15

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)